^
    Back
    Association details:
    Biomarker:EZH2 mutation
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:CPI-169 (EZH2 inhibitor) +
    CPI-203 (BET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    AACR-II 2020
    Title:

    Abstract 2925: Safety and efficacy of EZH2 and BRD4 dual targeting in EZH2Y641mut germinal centre-derived lymphoma

    Published date:
    05/15/2020
    Excerpt:
    ...CPI169 combination with the MYC-interfering drug, BET inhibitor CPI203, achieved a synergistic anti-proliferating activity in EZH2 mutated cases and in mice bearing EZH2mut DLBCL tumors.
    DOI:
    10.1158/1538-7445.AM2020-2925